VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675…
Johnson & Johnson (NYSE:JNJ) said on Tuesday that it would pay $1.75 billion in cash for Alios BioPharma, a private biotechnology company that is working on treatments for viral diseases. Johnson & Johnson (NYSE:JNJ) belongs to Healthcare sector. Its net profit margin is 21.20% and weekly performance is -3.03%. On last trading day company shares…
Ariad Pharmaceuticals (NASDAQ:ARIA Director Sarah J. Schlesinger bought 5,200 shares of Ariad Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, September 10th. The shares were purchased at an average cost of $5.73 per share, with a total value of $29,796.00. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly…
VIVUS Inc. (NASDAQ:VVUS) The company on Aug. 25 announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014…
